|Articles|February 25, 2016

PE Strat Outlook 2015

External Link - PharmaScienceStrategicOutlook2016.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava

ByNicholas Jacobus

April 2nd 2026

Organizations such as CVS Health have combined insurance, pharmacy benefit management, retail dispensing, and provider services. Credit: Stock.Adobe.com/monticellllo.

The New Antitrust Era: Why CVS-Style Healthcare Integration is Now the FTC’s Primary Target

ByThani Jambulingam, PhD

April 2nd 2026

Trump Administration’s Leadership Carousel Across Key Agencies

ByNicholas Jacobus

April 2nd 2026

More Than Just Pricing: MFN’s Impact on Pharma: Q&A with Lindsay Bealor Greenleaf

ByMike Hollan,Lindsay Bealor Greenleaf

April 2nd 2026

Changing a Cell’s Fate: Q&A with Yerem Yeghiazarians, MD

ByMike Hollan,Yerem Yeghiazarians, MD

April 2nd 2026

PE Strat Outlook 2015

Newsletter

Related Content

Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava

The New Antitrust Era: Why CVS-Style Healthcare Integration is Now the FTC’s Primary Target

Trump Administration’s Leadership Carousel Across Key Agencies

More Than Just Pricing: MFN’s Impact on Pharma: Q&A with Lindsay Bealor Greenleaf

Changing a Cell’s Fate: Q&A with Yerem Yeghiazarians, MD

Trending on PharmExec

FDA Approves Foundayo Under National Priority Voucher Program

Trump Administration’s Leadership Carousel Across Key Agencies

More Than Just Pricing: MFN’s Impact on Pharma: Q&A with Lindsay Bealor Greenleaf

The New Antitrust Era: Why CVS-Style Healthcare Integration is Now the FTC’s Primary Target

Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava